Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
Steris plc reported Q1 FY2027 results with revenue of $1,492.7 million, a 7.3% increase year-over-year, driven by higher volume and pricing across its Healthcare, AST, and Life Sciences segments. Gross margin expanded to 45.8%, up 70 basis points, as benefits from pricing and productivity offset inflationary pressures. However, operating cash flow decreased to $367.1 million from $420.0 million, reflecting a lower contribution from working capital that partially offset the higher net income.
Revenue
$1.49B
+7.30% YoY
Gross Margin
45.8%
+0.7 pts YoY
Operating Income
$285.8M
+16.18% YoY
Source: SEC XBRL
Steris (STE) reported Q1 FY2027 revenue of $1.49B, up 7.3% year over year. Operating margin was 19.1%, up 1.4 points from 17.7% a year earlier. Operating cash flow was $367.1M, down 12.6% year over year. STE's fiscal Q1 FY2027 corresponds to calendar Q2 2026.
Last 4 quarters: 2 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026This filing | 2.59 | 2.53 | Beat +2.5% |
| Mar 2026 | 2.83 | 2.88 | Miss -1.6% |
| Dec 2025 | 2.53 | 2.56 | Miss -1.1% |
| Sep 2025 | 2.47 | 2.37 | Beat +4.0% |
Reported EPS of $2.59 versus the $2.53 analyst consensus — a +2.5% beat for Jun 2026.
3 reported segments · SEC XBRL
Segment revenue totals $1.49B, which is the $1.49B of consolidated revenue on the income statement.
Compiled by AI from 10-Q Item 2 of this filing
Total revenues rose 7.3% to $1,492.7 million, with organic constant currency growth of 6.2% after adjusting for acquisitions and foreign exchange, reflecting volume and pricing gains across all segments.
Source: 10-Q Item 2 MD&A
Gross margin improved to 45.8% from 45.1%, with pricing contributing 100 basis points, productivity 40 bps, and favorable mix 40 bps, partly offset by 60 bps from inflation.
Source: 10-Q Item 2 MD&A
Free cash flow was $279.6 million, down from $326.5 million, as a lower contribution from working capital more than offset higher earnings.
Source: 10-Q Item 2 MD&A
On August 5, 2026, the company announced a plan to consolidate U.S. chemistries manufacturing, expecting pre-tax charges of $55-70 million through fiscal 2030 to enhance efficiency and capacity.
Source: 10-Q Item 2 MD&A
The Healthcare segment backlog increased to $444.0 million from $403.5 million a year earlier, driven by order timing and an acquisition.
Source: 10-Q Item 2 MD&A
Compiled by AI from this SEC filing · 0 high, 4 medium, 1 low
Operating cash flow fell 12.6% due to lower working capital contributions, which could signal challenges in managing receivables, inventory, or payables.
Source: 10-Q Cash Flow Statement (XBRL)
The company spent $115.5 million on share buybacks in the quarter, including $100 million under a new repurchase program, reducing cash reserves and potentially limiting financial flexibility.
Source: 10-Q Cash Flow Statement (XBRL)
The newly announced chemistries restructuring plan involves estimated pre-tax charges of $55-70 million and multi-year implementation, with risks of cost overruns, operational disruptions, or failure to achieve expected efficiencies.
Source: 10-Q Item 2 MD&A
The Healthcare segment accounted for 70.2% of total segment revenues, exposing the company to adverse changes in healthcare spending, regulatory shifts, or competitive pressures in that industry.
Source: 10-Q Segment Information (XBRL)
With 25% of revenues generated outside the United States (excluding Ireland), fluctuations in exchange rates could negatively impact reported revenues and earnings, as seen in the organic constant currency growth of 6.2% vs reported 7.3%.
Source: 10-Q Item 2 MD&A
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $B | 1.49 $B | 1.39 $B | +7.30% |
Cost of Revenue $M | 808.60 $M | 763.10 $M | +5.96% |
Gross Profit $M | 684.20 $M | 628.00 $M | +8.95% |
Operating Income $M | 285.80 $M | 246.00 $M | +16.18% |
Net Income $M | 200.10 $M | 177.40 $M | +12.80% |
R&D Expense $M | 28.60 $M | 26.40 $M | +8.33% |
SG&A Expense $M | 369.70 $M | 353.80 $M | +4.49% |
Answers draw on this SEC filing and the data on this page
Expected release date, analyst estimates & what to watch
STERIS plc delivered strong fiscal year 2026 results with revenue growing 8.7% to $5.94B and net income surging 27.3% to $782.3M, driven by operating leverage that expanded operating margin by 270 basis points to 18.6%.
STE reported strong financial performance in Q3 FY2026 with significant growth in revenue and net income, supported by improved operating efficiency and reduced long-term debt.
Other companies in Health Care Equipment